Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Navigate: Correlations HPO
There is one clinical trial.
This is a phase 1b, open-label study in adult healthy subjects. This clinical trial is designed to assess the safety, reactogenicity, and immunogenicity of the hAd5-S-Fusion+N-ETSD vaccine and select a dose for future studies.
Description: Incidence of MAAEs and SAEs through 1 week post final vaccine administration
Measure: Incidence of MAAEs and SAEs Time: 1 weekDescription: Incidence and severity of solicited local reactogenicity AEs through 1 week post final vaccine administration
Measure: Incidence and severity of solicited local reactogenicity AEs Time: 1 weekDescription: Incidence and severity of solicited systemic reactogenicity AEs through 1 week post final vaccine administration
Measure: Incidence and severity of solicited systemic reactogenicity AEs Time: 1 weekDescription: Incidence and severity of unsolicited AEs through 1 week post final vaccine administration
Measure: Incidence and severity of unsolicited AEs Time: 1 weekDescription: Incidence of MAAEs and SAEs through 30 days and 6 months post final vaccine administration
Measure: Incidence of MAAEs and SAEs Time: 30 days to 6 monthsDescription: Incidence and severity of unsolicited AEs through 30 days post final vaccine administration
Measure: Incidence and severity of unsolicited AEs Time: 30 daysDescription: Incidence of abnormal changes of laboratory safety examinations
Measure: Incidence of abnormal changes of laboratory safety examinations Time: 30 daysDescription: Changes in vital signs from Grades 1-4: - Fever - measured in (°C) or (°F)
Measure: Vital Signs - Fever Time: 30 daysDescription: Changes in vital signs from Grades 1-4: - Tachycardia - measured in beats per minute
Measure: Vital Signs - Tachycardia Time: 30 DaysDescription: Changes in vital signs from Grades 1-4: - Bradycardia - measured in how many beats per minute
Measure: Vital Signs - Bradycardia Time: 30 DaysDescription: Changes in vital signs from Grades 1-4: - Hypertension (systolic/diastolic) - measured in mm Hg
Measure: Vital Signs - Hypertension Time: 30 DaysDescription: Changes in vital signs from Grades 1-4: - Hypotension (systolic) - measured in mm Hg
Measure: Vital Signs - Hypotension Time: 30 DaysDescription: Changes in vital signs from Grades 1-4: - Respiratory Rate - measured in how many breaths per minute
Measure: Vital Signs - Respiratory Rate Time: 30 DaysDescription: GMFR in neutralizing antibody
Measure: GMFR Time: Day 387Description: GMT of S-specific, RBD-specific, and N-specific antibodies against 2019 novel coronavirus tested by ELISA in serum
Measure: GMT of S-specific, RBD-specific, and N-specific antibodies against 2019 novel coronavirus Time: Day 387Description: Percentage of subjects who seroconverted (as defined as 4-fold change in antibody titer relative to baseline)
Measure: Percentage of subjects who seroconverted Time: Day 387Description: GMFR in IgG titer
Measure: GMFR Time: Day 387Description: GMT of neutralizing antibody
Measure: GMT Time: Day 387Description: Seroconversion rate of neutralizing antibody (as defined as 4-fold change in antibody titer relative to baseline)
Measure: Seroconversion rate of neutralizing antibody Time: Day 387Description: CD8+ T-Cell activity against SARS-CoV-2 S protein, RBD, and N protein measured by ELISPOT assay
Measure: CD8+ T-Cell activity against SARS-CoV-2 S protein, RBD, and N protein Time: Day 387Description: CD4+ T-Cell activity against SARS-CoV-2 S protein, RBD, and N protein measured by standard immune assay
Measure: CD4+ T-Cell activity against SARS-CoV-2 S protein, RBD, and N protein Time: Day 387Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports